Mechanical prosthetic valve thrombosis after ChAdOx1-nCoV-19 vaccination: A case report
- PMID: 40477992
- PMCID: PMC9536874
- DOI: 10.1016/j.ihjccr.2022.09.008
Mechanical prosthetic valve thrombosis after ChAdOx1-nCoV-19 vaccination: A case report
Abstract
The ChAdOx1 nCoV-19 adenoviral vector-based vaccine was the first to be approved against COVID-19 in India. Vaccine induced thrombotic thrombocytopenia (VITT) is a rare but serious adverse effect of the ChAdOx1 nCoV-19 vaccine, causing widespread thrombosis and thrombocytopenia. A 22-year-old patient, who had undergone mechanical mitral valve replacement, presented to us one week after administration of 1st dose of the ChAdOx1 nCoV-19 Coronavirus vaccine with acute prosthetic heart valve thrombosis (PVT). Laboratory investigations revealed thrombocytopenia and high D-Dimer levels, suggestive of probable VITT. In this report, we highlight the importance of identification of VITT as a cause of PVT and discuss management options.
Keywords: Coronavirus; Heart valve diseases; Thrombosis; Vaccines.
© 2022 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.
Conflict of interest statement
No conflict of interest.
Figures



References
-
- Ritchie H., Mathieu E., Rodés-Guirao L., et al. https://ourworldindata.org/covid-vaccinations Coronavirus Pandemic (COVID-19). Our World Data [Internet]. 2020 Mar 5 [cited 2022 Jul 28]; Available from: